Loading…
Gujarat Kidney and Super Speciality (GKSL)₹154.87−2.66%Hospital
At the end of the Jun 2026 quarter, Gujarat Kidney and Super Speciality's shareholders were: promoters 71.44%, FIIs 4.85%, DIIs 0.56%, public 23.15%. Promoter holding is unchanged on the quarter. It had 18,302 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters | 71.44% | 71.44% | 71.44% |
| FIIs | 10.42% | 4.85% | 4.85% |
| DIIs | 1.68% | 0.56% | 0.56% |
| Public | 16.46% | 23.15% | 23.15% |
| Number of shareholders | 27,785 | 18,302 | 18,302 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Pragnesh Yashwantsinh Bharpoda | Promoter | 38.15% | 0.00 |
| Anitaben Nayak | Promoter | 11.15% | 0.00 |
| Yashwantsingh Motisingh Bharpoda | Promoter | 11.05% | 0.00 |
| Bhartiben Pragnesh Bharpoda | Promoter | 11.04% | 0.00 |
| Craft Emerging Market Fund Pcc-Citadel Capital Fund | FII | 1.66% | 0.00 |
| Khandelwal Finance Private Limited | Public | 1.66% | 0.00 |
Promoters held 71.44% of Gujarat Kidney and Super Speciality at the end of the Jun 2026 quarter.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 4.85% (unchanged at 4.85% a quarter earlier) and domestic institutions (DIIs) held 0.56% (unchanged at 0.56% a quarter earlier).
Gujarat Kidney and Super Speciality had 18,302 shareholders at the end of the Jun 2026 quarter.
Craft Emerging Market Fund Pcc-Citadel Capital Fund (FII) held 1.66% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.